Welcome to our dedicated page for Actinium Pharmaceuticals SEC filings (Ticker: ATNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Actinium Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Actinium Pharmaceuticals's regulatory disclosures and financial reporting.
Actinium Pharmaceuticals insider filing: Sandesh Seth, the company's Chief Executive Officer and a Director, reported a transaction dated 08/18/2025 relating to his common stock holdings in Actinium Pharmaceuticals (ATNM). The Form 4 discloses that 120,900 shares were withheld at a price of $1.71 to satisfy tax withholding obligations arising from the vesting of 300,000 restricted stock units (RSUs) that were granted to Mr. Seth on 08/17/2022. After the withholding, Mr. Seth beneficially owned 184,481 shares. The filing explains the RSUs were granted in exchange for previously issued warrants that had vested earlier and whose expiration dates and exercise were adjusted by the board to align his interests with stockholders.
Actinium Pharmaceuticals (ATNM) reported no revenue for the quarter and six months and recorded a net loss of $6.9 million for the three months and $22.8 million year-to-date, or $0.73 per share for six months on 31.2 million shares outstanding. Cash and cash equivalents totaled $59.9 million (plus $0.3 million restricted cash) versus $72.9 million at year-end, and stockholders’ equity declined to $19.0 million from $32.8 million.
The company recorded $8.8 million of stock-based compensation in the six-month period related to the cancellation of options, and operating expenses were $24.1 million for six months, driven by R&D and G&A. License consideration of $35.0 million received under its Immedica agreement remains recorded as long-term deferred revenue until EU regulatory milestones are satisfied. Material legal actions include a securities class action and consolidated derivative complaints; lead plaintiffs were recently appointed.
The Vanguard Group has filed Amendment No. 1 to Schedule 13G for Actinium Pharmaceuticals (ATNM), triggered by the 30 June 2025 reportable event. The filing discloses 1,371,840 ATNM common shares beneficially owned, equal to 4.39 % of the outstanding class, placing Vanguard below the 5 % threshold noted in Item 5.
According to Item 4, Vanguard holds no voting power—sole or shared—but retains dispositive authority over nearly all of the shares (sole: 1,362,947; shared: 8,893). Vanguard is filing in its capacity as an investment adviser (Rule 13d-1(b)(1)(ii)(E)); the ownership is on behalf of its advisory clients, none of which individually own more than 5 %. Certification in Item 10 confirms the stake is held in the ordinary course of business and not for the purpose of influencing control of ATNM.